As Novo Nordisk’s hotly anticipated Wegovy pill gets off to the races in the U.S., the company is making sure to cover its ...
Mani Foroohar, M.D., of Leerink Partners, says that the decision reflects “how sharp the departure has been between the prior ...
Eli Lilly and Innovent Biologics have deepened their ties with a new type of deal. | Eli Lilly and Innovent Biologics have ...
But now, 13 years after the FDA initially blessed it for skin cancer, the U.S. regulator has approved Keytruda as a second- ...
After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030 ...
As the U.S. backpedals on its mRNA investment, Mexico is embracing the technology through a new manufacturing pact with ...
Bayer has cooked up the next phase of its “See Your Risks” campaign, tapping Food Network star Jeff Mauro as its sous chef. ...
Chinese prosecutors have brought formal charges against AstraZeneca and its former executives following investigations into alleged illegal patient data collection and importation of drugs. | Chinese ...
J&J kicked off the new year with a bang, shelling out more than $78 million to air eight TV ads for Tremfya throughout ...
Novartis to seek full FDA approval for IgAN drug Vanrafia despite missing ph. 3 kidney function goal
It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...
Hims & Hers caused a firestorm last week when it revealed that it planned to launch a knockoff version of Novo Nordisk's new ...
Breast cancer drug Kisqali outperformed its 2025 sales target by 9%, while a portfolio of recent launches that includes radioligand therapy Pluvicto, kidney disease drugs Fabhalta and Vanrafia, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results